Valneva Expands its Commercial Operations with the Opening of its French Commercial Office
January 09 2020 - 1:00AM
Valneva Expands its Commercial Operations with the Opening of its
French Commercial Office
Saint-Herblain (France), January 9, 2020 –
Valneva SE (“Valneva” or “the Company”) today announced a further
expansion of its global commercial infrastructure with the opening
of a French commercial office in Lyon. The fully owned commercial
subsidiary, Valneva France SAS, will take direct control of sales
and marketing of IXIARO® and DUKORAL® in France with the aim of
accelerating sales growth of the vaccines.
Franck Grimaud, Chief Business Officer
of Valneva, commented, “Since regaining global
distribution rights of our Japanese encephalitis vaccine in 2015,
we have continued to expand our commercial infrastructure in key
travel markets. This allowed us to more than double our sales since
2015. Based on the deep experience that we have built and by giving
focus through a dedicated sales & marketing team, we expect to
increase penetration and sales in France.”
Valneva France SAS will be Valneva’s sixth
commercial country operation. The Company currently has direct
commercial presence in the United States, Canada, the Nordic
Countries, the United Kingdom and Austria.
About Valneva SE
Valneva is a specialty vaccine company providing
prevention against diseases with major unmet medical needs.
Valneva’s portfolio includes two commercial vaccines for travelers:
IXIARO®/JESPECT® indicated for the prevention of Japanese
encephalitis and DUKORAL® indicated for the prevention of cholera
and, in some countries, prevention of diarrhea caused by ETEC. The
Company has various clinical-stage vaccines in development
including unique vaccines against Lyme disease and chikungunya.
Valneva has operations in Austria, Sweden, the United Kingdom,
France, Canada and the US with approximately 490 employees. More
information is available at www.valneva.com.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineGlobal Head of Investor Relations & Corporate
CommunicationsM +33 (0)6 4516 7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2020_01_09_VLA_France_SAS_Commercial_Office_PR_EN_Final
Valneva (EU:VLA)
Historical Stock Chart
From Apr 2024 to May 2024
Valneva (EU:VLA)
Historical Stock Chart
From May 2023 to May 2024